---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-22-021688"
form_type: "8-K"
ticker: "GOVX"
cik: "0000832489"
company_name: "GeoVax Labs, Inc."
filed_at: "2022-09-01T23:59:59+00:00"
generated_at: "2026-06-23T18:14:45.536284+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# GeoVax appoints Nicole Lemerond, CFA, to its Board of Directors

## Summary
- Nicole Lemerond appointed to GeoVax Board, effective August 31, 2022.
- Ms. Lemerond brings over 25 years of healthcare finance experience including investment management, M&A, and private equity.
- She has been appointed to the Audit Committee and will receive standard non-employee director compensation.
- Her background includes roles at Lehman Brothers and The Carlyle Group.

## SEC filing metadata
- accession: 0001437749-22-021688
- form_type: 8-K
- ticker: GOVX
- cik: 0000832489
- company_name: GeoVax Labs, Inc.
- filed_at: 2022-09-01T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/832489/000143774922021688/0001437749-22-021688-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/832489/000143774922021688/govx20220901_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-22-021688
- JSON: https://secwatch.observer/filing/0001437749-22-021688.json
- Plain text: https://secwatch.observer/filing/0001437749-22-021688.txt

## Key facts
- Executive change
  Nicole Lemerond was appointed as Director at GeoVax Labs, Inc..
  - Action: appointed
  - Role: Director
  source text: On August 31, 2022, our Board of Directors (the “Board”) appointed Nicole Lemerond to the Board, effective as of August 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/832489/000143774922021688/0001437749-22-021688-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.